Jason Adair Sells 688 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 688 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $87.53, for a total transaction of $60,220.64. Following the sale, the insider owned 216,438 shares in the company, valued at $18,944,818.14. The trade was a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, July 13th, Jason Adair sold 7,863 shares of Liquidia stock. The stock was sold at an average price of $71.51, for a total transaction of $562,283.13.

Liquidia Stock Performance

NASDAQ:LQDA opened at $86.80 on Friday. Liquidia Corporation has a 12 month low of $16.82 and a 12 month high of $91.10. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm has a market capitalization of $7.72 billion, a PE ratio of 620.04 and a beta of 0.55. The business’s fifty day moving average price is $73.31 and its 200 day moving average price is $51.72.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. The firm’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, sell-side analysts anticipate that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. TCG Crossover Management LLC acquired a new stake in shares of Liquidia during the third quarter worth about $38,887,000. MPM Bioimpact LLC raised its stake in Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in Liquidia during the 3rd quarter worth approximately $12,571,000. Bank of America Corp DE grew its stake in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Liquidia by 428.3% in the fourth quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after purchasing an additional 341,009 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LQDA has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. HC Wainwright set a $36.00 price target on shares of Liquidia in a research report on Friday, July 24th. Needham & Company LLC raised their price objective on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Stephens set a $130.00 target price on Liquidia in a report on Friday, July 24th. Finally, Bank of America reissued a “neutral” rating and issued a $79.00 target price (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $86.18.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).